DNLI Q2 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M+292.3% YoY

Gross Profit

$23M100.0% margin

Operating Income

-$62M-269.5% margin

Net Income

-$61M-264.6% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

+189.5%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$55M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$437M

Stockholders' Equity

$1.1B

Cash & Equivalents

$486M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$6M	+292.3%
Gross Profit	$23M	$6M	+292.3%
Operating Income	-$62M	-$61M	-0.9%
Net Income	-$61M	-$59M	-3.3%

Revenue Segments

Alzheimer's Disease Services

$3M100%